[go: up one dir, main page]

WO2025030097A3 - Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et méthodes associées - Google Patents

Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et méthodes associées Download PDF

Info

Publication number
WO2025030097A3
WO2025030097A3 PCT/US2024/040724 US2024040724W WO2025030097A3 WO 2025030097 A3 WO2025030097 A3 WO 2025030097A3 US 2024040724 W US2024040724 W US 2024040724W WO 2025030097 A3 WO2025030097 A3 WO 2025030097A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
pharmaceutical compositions
herpes simplex
simplex virus
related methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/040724
Other languages
English (en)
Other versions
WO2025030097A2 (fr
Inventor
Ugur Sahin
Michael Steven ROONEY
Ekaterina ESAULOVA
Adam ZUIANI
Theresa ADDONA
Asaf PORAN
Scott GOULDING
Ricardo Sanchez Velazquez
Julia UEBELE
Alptekin GÜLER
Yu-Jung Lu
Harvey Friedman
Sita Awasthi
Gary H. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
University of Pennsylvania Penn
Original Assignee
Biontech SE
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE, University of Pennsylvania Penn filed Critical Biontech SE
Publication of WO2025030097A2 publication Critical patent/WO2025030097A2/fr
Publication of WO2025030097A3 publication Critical patent/WO2025030097A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne des compositions pharmaceutiques pour l'administration d'antigènes du VHS (par exemple, un vaccin contre le VHS) et des technologies associées (par exemple, des composants correspondants et/ou des méthodes associées).
PCT/US2024/040724 2023-08-03 2024-08-02 Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et méthodes associées Pending WO2025030097A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363517362P 2023-08-03 2023-08-03
US63/517,362 2023-08-03
US202463639547P 2024-04-26 2024-04-26
US63/639,547 2024-04-26

Publications (2)

Publication Number Publication Date
WO2025030097A2 WO2025030097A2 (fr) 2025-02-06
WO2025030097A3 true WO2025030097A3 (fr) 2025-03-06

Family

ID=92543382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/040724 Pending WO2025030097A2 (fr) 2023-08-03 2024-08-02 Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et méthodes associées

Country Status (1)

Country Link
WO (1) WO2025030097A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2019035066A1 (fr) * 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
WO2023107999A2 (fr) * 2021-12-08 2023-06-15 Modernatx, Inc. Vaccins à arnm contre le virus de l'herpès simplex
WO2023147090A1 (fr) * 2022-01-27 2023-08-03 BioNTech SE Compositions pharmaceutiques pour administration d'antigènes du virus herpès simplex et méthodes associées

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4959049A (en) 1989-09-11 1990-09-25 Smirmaul Heinz J Tip for a phacoemulsification needle
CA2044593C (fr) 1989-11-03 2004-04-20 Kenneth L. Brigham Methode d'expression in vivo de genes etrangers fonctionnels
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
JP3556323B2 (ja) 1995-06-15 2004-08-18 富士通株式会社 中継装置
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU749881B2 (en) 1998-02-03 2002-07-04 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
ES2356934T3 (es) 2001-06-05 2011-04-14 Curevac Gmbh ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL.
EP1519714B1 (fr) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Appareil liposomal et procedes de fabrication
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
WO2005121348A1 (fr) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans des lipides
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2006274413B2 (en) 2005-07-27 2013-01-10 Arbutus Biopharma Corporation Systems and methods for manufacturing liposomes
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
EP3757090B1 (fr) 2008-11-10 2024-06-12 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
WO2011000106A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques
US20130022649A1 (en) 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CA2784568A1 (fr) 2009-12-18 2011-06-23 Martin A. Maier Particules de lipide destinees a la distribution d'acides nucleiques
WO2011141705A1 (fr) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci
US9012498B2 (en) 2010-06-03 2015-04-21 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CA3107288A1 (fr) 2011-06-08 2012-12-13 Translate Bio, Inc. Compositions de nanoparticules lipides et procedes pour le transfert d'arnm
WO2013016058A1 (fr) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques contenant du bis-azote pour administration d'oligonucléotide
WO2013049328A1 (fr) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
WO2013086373A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides pour l'administration d'agents actifs
EP2788316B1 (fr) 2011-12-07 2019-04-24 Alnylam Pharmaceuticals, Inc. Lipides biodégradables ramifiés à terminaisons alkyle et cycloalkyle destinés à l'administration d'agents actifs
CA2856742A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides biodegradables pour l'administration d'agents actifs
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
WO2014008334A1 (fr) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Formulations de particules de lipide et d'acide nucléique sans agrégats et stables
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
EP3871696B1 (fr) 2013-10-22 2025-03-19 Translate Bio, Inc. Formulations de lipides pour l'administration d'arn messager
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
WO2016005004A1 (fr) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilisation de séquences d'adn codant pour une séquence poly (a)
EP3294885B1 (fr) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Procédé de production d'arn
AU2016285852B2 (en) 2015-06-29 2020-12-17 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017059902A1 (fr) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh Séquences utr 3' permettant la stabilisation d'arn
LT3368507T (lt) 2015-10-28 2023-03-10 Acuitas Therapeutics Inc. Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui
EP4582098A3 (fr) 2015-11-09 2025-12-24 CureVac SE Molécules d'acide nucléique optimisées
US10019502B2 (en) 2015-11-27 2018-07-10 Netapp Inc. Non-disruptive baseline and resynchronization of a synchronous replication relationship
HRP20211745T1 (hr) 2016-04-22 2022-02-04 BioNTech SE Postupci za dobivanje jednolančane rnk
EP3532103B1 (fr) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Formulations de nanoparticules lipidiques
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
EP3897702A2 (fr) 2018-12-21 2021-10-27 CureVac AG Arn pour vaccins antipaludiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2019035066A1 (fr) * 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations
WO2023107999A2 (fr) * 2021-12-08 2023-06-15 Modernatx, Inc. Vaccins à arnm contre le virus de l'herpès simplex
WO2023147090A1 (fr) * 2022-01-27 2023-08-03 BioNTech SE Compositions pharmaceutiques pour administration d'antigènes du virus herpès simplex et méthodes associées

Also Published As

Publication number Publication date
WO2025030097A2 (fr) 2025-02-06

Similar Documents

Publication Publication Date Title
MX2024009250A (es) Composiciones farmaceuticas para la administracion de antigenos del virus del herpes simple y metodos relacionados
WO2023107999A3 (fr) Vaccins à arnm contre le virus de l'herpès simplex
WO2022221440A8 (fr) Vaccins combinés contre le coronavirus et la grippe
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
WO2021226267A3 (fr) Compositions de virus adéno-associés compatibles entre espèces et leurs méthodes d'utilisation
WO2021242776A3 (fr) Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
MX2025008754A (es) Composiciones farmaceuticas para la administracion de antigenos de glicoproteina c, glicoproteina d y glicoproteina e del virus del herpes simple y metodos relacionados
MX2024014492A (es) Composiciones de arn para la administracion de antigenos de viruela simica y metodos relacionados
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
WO2023064612A3 (fr) Compositions pharmaceutiques pour l'administration d'antigènes viraux et méthodes associées
WO2021262910A3 (fr) Tubulysines et conjugués tubulysines-protéines
WO2022132596A3 (fr) Antigènes spécifiques de tissu pour une immunothérapie anticancéreuse
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
WO2022032073A3 (fr) Modulateurs de trpml
WO2021243248A3 (fr) Adjuvants pour vaccins contre le coronavirus associé au syndrome respiratoire aigu sévère (sras-cov)
PH12022552075A1 (en) Hpv vaccine
WO2020028719A3 (fr) Compositions comprenant le virus 1 de l'herpès simplex pour les utiliser dans des procédés de traitement et de prévention du cancer
WO2022106902A3 (fr) Dérivés de benzènesulfonamide et leurs utilisations
WO2021211629A3 (fr) Procédés de préparation et d'utilisation d'un vaccin contre le coronavirus
WO2025030097A3 (fr) Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et méthodes associées
WO2022125746A3 (fr) Lymphocytes t spécifiques d'un virus et procédés de traitement et de prévention d'infections virales
WO2023192949A3 (fr) Compositions et procédés pour induire une réponse immunitaire contre le virus d'epstein-barr
WO2021074286A3 (fr) Vaccins contre le virus de la grippe et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24762084

Country of ref document: EP

Kind code of ref document: A2